Melatonin Synergises the Chemotherapeutic Effect of Temozolomide in Glioblastoma by Suppressing NF ‐ κB / COX ‐2 Signalling Pathways
Journal of Cellular and Molecular Medicine · 2025-08 · 29 (15)
DOI: 10.1111/jcmm.70778 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Cellular and Molecular Medicine, online erschienen am 13.08.2025. Verfasst von Hong Tang und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Integrated Medicine, College of Integrated Medicine, Dalian Medical University, Dalian, People's Republic of China. Hauptthemen laut MEDLINE: Melatonin, Temozolomide, Glioblastoma, NF-kappa B. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 67 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Funding of Life and Health Sector Guidance Plan Projects of Dalian in 2024, the Interdisciplinary Research Cooperation Project Funding of Dalian Medical University, Research on cancer prevention and treatment in 2022 by Chen Xiaoping Science.
Abstract (Originalsprache)
Glioblastoma (GBM) is an aggressive and highly malignant primary brain tumour, accounting for a significant proportion of adult brain tumours. It is associated with a poor prognosis and high recurrence rates. Although temozolomide (TMZ) remains the standard first‐line chemotherapy for GBM, its clinical efficacy is often limited by the development of drug resistance and toxic effects on normal tissues. Melatonin (Mel), a natural indoleamine synthesised by the pineal gland, has demonstrated synergistic anti‐tumour effects when combined with various chemotherapy agents in multiple studies. This study investigates the synergistic potential of Mel to enhance TMZ's therapeutic efficacy against GBM. The results demonstrate that the combination of Mel and TMZ significantly inhibits glioblastoma cell proliferation, migration, and invasion. Mechanistically, this synergistic effect is mediated through the NF‐κB/COX‐2 signalling pathway. Mel enhances TMZ's anti‐tumour activity by inhibiting IκBα phosphorylation, suppressing NF‐κB activation, and downregulating COX‐2 expression. Additionally, the combination treatment induced apoptosis via activation of the Caspase‐3 pathway. These results suggest that Mel can potentiate the therapeutic efficacy of TMZ in glioblastoma treatment, offering a promising strategy to overcome TMZ resistance while reducing its associated toxicity.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Integrated Medicine, College of Integrated Medicine, Dalian Medical University, Dalian, People's Republic of China.
- The First Affiliated Hospital of Dalian Medical University, Dalian, People's Republic of China.
ORCID-Profile: Zheng Sun
Förderung
- Funding of Life and Health Sector Guidance Plan Projects of Dalian in 2024
- the Interdisciplinary Research Cooperation Project Funding of Dalian Medical University
- Research on cancer prevention and treatment in 2022 by Chen Xiaoping Science
Zitieren
APA
Tang, H., Dai, Q., Zhao, Z., Ge, W., Li, D., Chang, Z., Pi, P., Li, J., & Sun, Z. (2025). Melatonin Synergises the Chemotherapeutic Effect of Temozolomide in Glioblastoma by Suppressing NF ‐ κB / COX ‐2 Signalling Pathways. Journal of Cellular and Molecular Medicine, 29(15). https://doi.org/10.1111/jcmm.70778
Vancouver
Tang H, Dai Q, Zhao Z, Ge W, Li D, Chang Z, et al. Melatonin Synergises the Chemotherapeutic Effect of Temozolomide in Glioblastoma by Suppressing NF ‐ κB / COX ‐2 Signalling Pathways. Journal of Cellular and Molecular Medicine. 2025;29(15). doi:10.1111/jcmm.70778
BibTeX
@article{Tang2025,
author = {Tang, Hong and Dai, Qi and Zhao, Ziyan and Ge, Weiye and Li, Danlei and Chang, Zelin and Pi, Penglai and Li, Jia and Sun, Zheng},
title = {Melatonin Synergises the Chemotherapeutic Effect of Temozolomide in Glioblastoma by Suppressing NF ‐ κB / COX ‐2 Signalling Pathways},
journal = {Journal of Cellular and Molecular Medicine},
year = {2025},
volume = {29},
number = {15},
doi = {10.1111/jcmm.70778}
}
EUVIMED